Erratum: An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976
ErratumColombo GL, Caruggi M, Di Matteo, et al. 2008. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976.Page 972, Results, r...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5ebb63c24da047e383dd2b549e53c10b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | ErratumColombo GL, Caruggi M, Di Matteo, et al. 2008. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967–976.Page 972, Results, right column, last paragraph. The second sentence should read:In the simulated cohort of 1000 patients, the values with aripiprazole for 26 weeks showed the avoidance of 34 events of diabetes over 5 years (28 in discounted scenario), resulting in total cost savings of €1,933.24 (€1,472.52 in discounted scenario).Page 973, Table 5:Under Events avoided/1000 schizophrenia patients (5 years): 18 should read 28.Under Cost/metabolic syndrome avoided (5 years): −€2,860.52 should read −€1,852.73. |
|---|